BASEL, Switzerland, July 7, 2026
Roche announced that it will present extensive new clinical and diagnostic data from its Alzheimer’s disease portfolio during the Alzheimer’s Association International Conference (AAIC) 2026, taking place in London from July 12–15. The company will deliver 18 oral and poster presentations highlighting advances across investigational therapeutics and blood-based diagnostics, underscoring its integrated strategy to improve earlier detection, diagnosis, treatment, and prevention of Alzheimer’s disease.
Trontinemab Program Highlights Long-Term Data and Phase 3 Prevention Strategy
A major focus of Roche’s presentations will be trontinemab, the company’s investigational Brainshuttle™ bispecific amyloid-beta monoclonal antibody, which is designed to enhance drug delivery across the blood-brain barrier. During a dedicated 90-minute Featured Research Session, Roche will present five oral presentations covering long-term safety, amyloid plaque removal, biomarker outcomes, and dosing simulations from the ongoing Phase Ib/IIa Brainshuttle AD open-label extension study.
The company will also unveil the design of PrevenTRON, its planned Phase III clinical trial evaluating trontinemab in cognitively unimpaired individuals who are at high risk of developing symptomatic Alzheimer’s disease. The study will utilize Roche’s recently CE-marked Elecsys® pTau217 blood test to help identify eligible participants with early Alzheimer’s pathology before symptoms emerge. Data from the Brainshuttle AD program have also informed dosing strategies for the ongoing Phase III TRONTIER 1 and TRONTIER 2 studies in patients with early symptomatic Alzheimer’s disease.
Roche Expands Blood-Based Alzheimer’s Diagnostics
Advertisement
Roche will also present multiple studies highlighting the clinical utility of its blood-based Alzheimer’s diagnostic portfolio. New data will evaluate the performance of the Elecsys pTau217 blood test, which recently received CE Mark certification as both a rule-in and rule-out diagnostic assay for amyloid pathology in primary and secondary care settings. Additional presentations will examine the approved Elecsys pTau181 blood test, including performance across diverse patient populations, sample stability under routine clinical storage conditions, and its potential to improve implementation of blood-based Alzheimer’s testing in everyday clinical practice. Roche will also host an educational symposium discussing how scalable blood-based biomarkers can help reduce diagnostic delays and improve patient access to disease-modifying therapies.
Broader Neurodegenerative Research Strengthens Roche’s Alzheimer’s Strategy
Beyond amyloid-targeting therapies, Roche will present new research exploring the NLRP3 inflammasome as a promising neuroimmune target for Alzheimer’s disease and other neurodegenerative disorders, including Parkinson’s disease. Additional presentations will examine external control methodologies in Alzheimer’s clinical trials, neuroimaging analyses of amyloid removal, caregiver burden, and strategies to improve diversity and accessibility in Alzheimer’s clinical trial enrollment. Roche’s expanding Alzheimer’s portfolio includes investigational therapies such as trontinemab, nivegacetor, and RG6627, alongside its growing portfolio of blood-based and cerebrospinal fluid biomarkers including Elecsys pTau181, Elecsys pTau217, and ApoE4 assays. Through the combined development of innovative therapeutics and diagnostics, Roche aims to accelerate earlier diagnosis and intervention while advancing its long-term goal of slowing, stopping, or ultimately preventing the progression of Alzheimer’s disease
Source: Roche press release
